Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

ntial growth in clinical product sales, and demand for certain products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the fact that the audit for 2008 has not yet been completed, and therefore could have audit-related adjustments; the impact of the significant global economic downturn on the company's target markets; success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for MRSA and other Healthcare Associated Infections (HAIs); the company's ability to successfully introduce and sell products in clinical markets other than HAIs; the mix of products sold; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the company's reliance on distributors in some regions to market, sell and support its products; the impact of competitive products and pricing; and the company's ability to manage geographically-dispersed operations. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and its other reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that Innovative ... e-Journal and producer of Food Labs Conference , ... the co-location of Food Labs Conference to be held in ... fee to attend the two-day Food Lab Conference, March 4-5. ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Rao and his team are researching nano-scale cantilevers that have ... or gases in the air. Put them into a small ... alerts in battle, in industry, in health care and even ... to do this work has been something we,ve only seen ...
... 98% and Adjusted EBITDA Up 70% Year-Over-Year, ... Inc. (NYSE: WX ), a leading pharmaceutical, ... with operations,in China and the United States, today ... ended September 30, 2008. During the quarter,WuXi,s net ...
... announced today the successful closure of its Starfish ... capital fundraising in,Australia. The fund will invest in ... of this fundraising is an endorsement of Starfish ... the development of,innovative companies that, with the right ...
Cached Biology Technology:Clemson researchers advance nanoscale electromechanical sensors 2WuXi PharmaTech Announces Third Quarter 2008 Results 2WuXi PharmaTech Announces Third Quarter 2008 Results 3WuXi PharmaTech Announces Third Quarter 2008 Results 4WuXi PharmaTech Announces Third Quarter 2008 Results 5WuXi PharmaTech Announces Third Quarter 2008 Results 6WuXi PharmaTech Announces Third Quarter 2008 Results 7WuXi PharmaTech Announces Third Quarter 2008 Results 8WuXi PharmaTech Announces Third Quarter 2008 Results 9WuXi PharmaTech Announces Third Quarter 2008 Results 10WuXi PharmaTech Announces Third Quarter 2008 Results 11WuXi PharmaTech Announces Third Quarter 2008 Results 12WuXi PharmaTech Announces Third Quarter 2008 Results 13Starfish Ventures Closes Australia's Largest Venture Capital Fund With $185 Million Tech Fund 2
(Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia ... makes testing safer, easier, faster and cheaper. , ... is commonly found in soils all over the world ... both humans and animals. The bacteria can survive in ... B. anthracis may occur through skin contact, inhalation ...
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... honored Clemson professor Rajendra Singh Thursday as a ... and expand solar deployment in the residential, commercial ... Banks Professor of Electrical and Computer Engineering and ... considered a local hero leading the charge across ... in solar power and driving policy changes at ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3Patented research remotely detects nitrogen-rich explosives 2White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... are the most populous organisms on the planet. They ... habitats by means of genetic variations that provide the ... what scientists believe is a random mutation and exchange ... that sometimes confers an advantage, and which then becomes ...
... to experience a "moderate" regional "red tide" this spring and ... to study the toxic algae that causes the bloom. The ... beings, however the toxins they produce can accumulate in filter-feeding ... shellfish poisoning (PSP) in humans who consume them. Under ...
... honored as the 2012 recipient of the ACMG Foundation/Signature ... College of Medical Genetics (ACMG) 2012 Annual Clinical Genetics ... for the award for her platform presentation, "Triheptanoin Therapy ... Ms. Barone will complete her Doctor of Medicine degree ...
Cached Biology News:Study shows unified process of evolution in bacteria and sexual eukaryotes 2Study shows unified process of evolution in bacteria and sexual eukaryotes 3Researchers report potential for a 'moderate' New England 'red tide' in 2012 2Researchers report potential for a 'moderate' New England 'red tide' in 2012 3Researchers report potential for a 'moderate' New England 'red tide' in 2012 42012 ACMG Foundation/Signature Genomic Laboratories Travel Award winner announced 2
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Silica bead method is an economic method of DNA extraction from agarose...
DTT, 25g...
... Agarose overlays are commonly ... Many commercial "DNA grade" agaroses ... toxic to insect cells or ... to obtain good overlays. Novagen's ...
Biology Products: